Live Support
Patient Co-pay Support
The Neulasta FIRST STEP® Co-pay Coupon Program helps eligible patients meet their Neulasta® deductible, co-insurance, and/or co-payment (out-of-pocket) requirements.* Additional benefits for your patient include:
- No income eligibility requirement
- No out-of-pocket cost for initial injection†
- Maximum out-of-pocket cost for subsequent injections is $25†
- One simple phone call to enroll
*Additional eligibility requirements may apply and the program is subject to certain limitations.
†Total program benefits may not exceed $5000 per patient per six-month period as defined by the program. Patient is responsible for costs above these amounts. Program benefits are limited to covering charges for the Neulasta® product, and do not cover ancillary costs associated with a Neulasta® treatment, including but not limited to physician, nursing, and office administration charges. Please visit AmgenFIRSTSTEP.com for full program requirements and limitations.
Enroll your practice today in the Amgen First Step™ Program 1-888-65-STEP1 (1-888-657-8371) www.AmgenFIRSTSTEP.com Fax: 1-888-407-9787
Enroll your practice
Enrollment is simple. Just call 1-888-65-STEP1 (1-888-657-8371) between 9 AM and 8 PM EST.
Determining patient eligibility
Once your practice is enrolled, you or your patient can determine eligibility. The Neulasta FIRST STEP® Co-pay Coupon Program is open to patients who meet the following criteria:
- A patient appropriate for Neulasta® treatment
- Currently have commercial health insurance that covers medication costs for Neulasta® under a medical benefit plan
- Not a participant in Medicare, Medicaid, or another federally funded healthcare program
- Not a resident of, or receiving treatment in, the state of Massachusetts
See complete eligibility requirements
Ongoing eligibility in the Amgen FIRST STEP™ program is contingent on submission of the required Explanation of Benefits (EOB) form by the patient's healthcare provider's office within 45 days of your treatment covered by the program. If a patient's co-insurance or co-payment exceeds $1,000 for an applicable injection, the balance in excess of $1,000 will be applied to the Amgen FIRST STEP™ program card once the patient's EOB form is processed by the program. Once that form has been processed, office staff simply need to swipe the card at the patient's next visit to receive payment for amounts due to the clinic/institution. There is no retroactive coverage available under this program. Any treatment prior to the patient's enrollment date will be considered retroactive and therefore not eligible for Amgen FIRST STEP™ benefits.
Starting January 1, 2012, eligible patients must re-enroll in the program on an annual basis for benefit coverage of a single course of treatment. Eligible patients may re-enroll at any time when a new course of treatment with a covered Amgen product is initiated.
Amgen reserves the right to modify or terminate this program, in whole or in part, without notice at any time. The program is not valid where prohibited by law.
Help Activate a Patient's Card
Once a patient has a Neulasta First Step® Co-pay Coupon Card, you can help them activate it, or they can do it themselves by calling 1-888-65-STEP1 (1-888-657-8371)1-888-657-8371.
Cards can also be activated online.
Indication
Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Neulasta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Important Safety Information
Do not administer Neulasta to patients with a history of serious allergic reactions to pegfilgrastim or Filgrastim.
Splenic rupture, including fatal cases, can occur following the administration of Neulasta. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving Neulasta.
Acute respiratory distress syndrome (ARDS) can occur in patients receiving Neulasta. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving Neulasta for ARDS. Discontinue Neulasta in patients with ARDS.
Serious allergic reactions, including anaphylaxis, can occur in patients receiving Neulasta. The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue Neulasta in patients with serious allergic reactions.
Severe sickle cell crises can occur in patients with sickle cell disorders receiving Neulasta. Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving Filgrastim, the parent compound of pegfilgrastim.
The granulocyte colony-stimulating factor (G-CSF) receptor, through which pegfilgrastim and Filgrastim act, has been found on tumor cell lines. The possibility that pegfilgrastim acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim is not approved, cannot be excluded.
Bone pain and pain in extremity occurred at a higher incidence in Neulasta-treated patients as compared with placebo-treated patients.
© 2011 Amgen Inc. All rights reserved. MC49791-B
